Nanjing Vazyme Biotech Co., Ltd (SHSE: 688105)
Health Care · Biotechnology · CN
CN¥27.24
+2.52% today · +53.3% 1Y
Nanjing Vazyme Biotech Co., Ltd (SHSE: 688105) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.10B and employs 3,002 people.
Over the last twelve months the share price has gained 53.3%, trading between 12.89 and 29.16.
Tweenvest scores Nanjing Vazyme Biotech Co., Ltd across four factors: quality 66/100, value 32/100, growth 0/100, dividend 46/100. Its strongest factor is quality.
688105 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.10B
- Revenue (TTM)
- $216.72M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- 1.41%
- Beta (5Y)
- 0.65
- 52-week high
- CN¥29.16
- 52-week low
- CN¥12.89
- Avg volume (3M)
- —
- Shares outstanding
- 516.99M
- Employees
- 3,002
- Next earnings
- —
About Nanjing Vazyme Biotech Co., Ltd
Nanjing Vazyme Biotech Co., Ltd., a prominent biotechnology firm, specializes in the comprehensive investigation, development, and manufacturing of essential biological components. These core offerings include enzymes, antigens, antibodies, and unique polymer organic compounds. The company's extensive product portfolio encompasses a broad spectrum of scientific research reagents. This range features solutions for advanced techniques such as PCR cloning and point mutation, nucleic acid extraction, reverse transcription, quantitative PCR (qPCR), cell and protein analysis, gene editing applications, and user-friendly instant granule formulations. Furthermore, Vazyme provides sophisticated reagents crucial for high-throughput sequencing library construction, including those for DNA and RNA library preparation, single-cell epigenetics, magnetic bead-based methodologies, quantitative assays, and the effective storage and extraction of cell-free DNA. Complementing these, the company also delivers a variety of biomedical reagents and related services. Vazyme's diverse clientele spans scientific research institutions, specialized high-throughput sequencing service providers, manufacturers of molecular diagnostic reagents, pharmaceutical enterprises, contract research organizations (CROs), hospitals, and other healthcare facilities. Established in 2012, the company maintains its headquarters in Nanjing, China.
- ISIN
- CNE100004ZK3
- Founded
- 2012
- Listed since
- Nov 15, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.NasdaqGM: AUPH | $2.13B | $16.22 | +1.31% |
| Wuhan Healthgen Biotechnology Corp.SHSE: 688765 | $2.12B | CN¥39.84 | -2.95% |
| BioCryst Pharmaceuticals, Inc.NasdaqGS: BCRX | $2.12B | $8.29 | -1.31% |
| SK bioscience Co.,Ltd.KOSE: A302440 | $2.12B | ₩36,500.00 | +2.10% |
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | $2.09B | $22.38 | -5.29% |
| Vericel CorporationNasdaqGM: VCEL | $2.06B | $40.05 | -0.25% |
| UroGen Pharma Ltd.NasdaqGM: URGN | $2.02B | $36.98 | -10.68% |
| OliX Pharmaceuticals, IncKOSDAQ: A226950 | $1.97B | ₩116,800.00 | +13.73% |
Figures last refreshed Oct 4, 2026.